The Russian Sputnik V vaccine is 91.6% effective at preventing symptomatic Covid-19, according to preliminary results from a phase 3 trial published in The Lancet on Tuesday, placing it in a similar league to the mRNA vaccines developed by Pfizer-BioNtech and Moderna.

The publication is important because scientists have previously expressed concern about Russia’s decision to start wide-scale vaccination with Sputnik V before releasing phase 3 trial data for public scrutiny, and the haste with which more than a dozen other nations have approved the shot...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now